Listen
Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use in the extension of indication “treatment of osteoporosis associated with long-term systemic corticosteroid therapy in postmenopausal women and men at increased risk of fracture".
-
Clinical Benefit
| Substantial |
The actual benefit of ACLASTA is substantial. |
Clinical Added Value
| no clinical added value |
The transparency Committee considers that ACLASTA does not provide an improvement in actual benefit (V) in comparison with ACTONEL in the management of corticosteroid-induced osteoporosis. |
English version
Contact Us
Évaluation des médicaments
